EPO and chronic kidney disease: In summary, our study has shown that Sphk2 is a putative novel pharmacological target in the renal Epo synthesis path, suggesting that selective inhibition of Sphk2 may not only reduce the progression of fibrosis in CKD, but may also directly increase Epo synthesis and prevent the development of anemia in CKD patients.